Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer

In a placebo-controlled randomised study of the platelet-derived growth factor receptor (PDGFR) inhibitor imatinib mesylate and docetaxel in metastatic prostate cancer with bone metastases (n=116), no significant differences in progression-free and overall survival were observed. To evaluate pharmac...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Main Authors:	Mathew, P, Thall, P F, Wen, S, Bucana, C, Jones, D, Horne, E, Oh, W K, Morris, M J, Lee, Y-C, Logothetis, C J, Lin, S-H, Fidler, I J
Format:	Artigo
Sprog:	Inglês
Udgivet:	Nature Publishing Group 2008
Fag:	Clinical Study
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC2579696/ https://ncbi.nlm.nih.gov/pubmed/18841158 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604706
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer

Lignende værker